These drugs are for people who test positive and need something for mild to moderate suffering from the virus….
They are a treatment, not a preventative…
The Food and Drug Administration (FDA) issued an emergency use authorization on Monday for an Eli Lilly antibody drug to treat mild to moderate cases of COVID-19.
The FDA’s authorization of bamlanivimab will permit the federal government to distribute the drug to state and territorial health departments to give to certain facilities. The U.S. already committed last month to 300,000 doses of the experimental drug, paying Eli Lilly $375 million.
People who are 12 years or older, weigh at least 40 kilograms and are at high risk of developing severe COVID-19 and/or hospitalization will be allowed to take the drug under the authorization. Those at high risk include people 65 years or older and those who have preexisting health conditions….
Eli Lilly’s deal with the U.S. government came after federal researchers determined the drug had little clinical benefit for hospitalized COVID-19 patients. But the company said its drug will assist those earlier in the COVID-19 infection process….
The author of the linked piece has two errors in their piece…
The drugs are for moderate virus cases , but the piece also says for severe cases and the NY Times linked piece which is featured also at the PDog does NOT show increases in virus cases…He show’s just the opposite….